Feed CRON
CR

Cronos Group Inc. CRON NASDAQ · Healthcare · Canada

$3.04 -1.30% -$0.04

Summary

58 / 100 · Bulios Score

What speaks for it

  • Out of every 100 USD of revenue, 28 USD is left as net profit.
  • Revenue grew by 20% a year over the last 3 years.
  • It holds more cash than debt: $411.2M against $1.21M.
  • The share price is below the Bulios Fair Price.

What to watch

  • It earns only 0.8 USD a year on every 100 USD of invested capital.
  • Earnings per share swing sharply from year to year.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Undervalued Price today $3.04

By our assumptions the business is worth more than its shares cost today.

P/E today 19.6
Drug Manufacturers - Specialty & Generic industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 19.6 USD for 1 USD of yearly profit.

Valuation in detail

Is it growing?

Yes, fast

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue grew by 26% a year over 5 years. Over the last 3 years it grew by 20% a year.

Growth in detail

Does it make money?

Very well

Where 100 USD of revenue goes

Net profit, industry median (Drug Manufacturers - Specialty & Generic) 9.9 USD

Out of every 100 USD of revenue, 28 USD is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

It could repay all its debt from a single year of free cash flow. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Neutral

Today's price within the analysts' price targets

The average target of $3.15 is 3.6% above today's price. 20% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2025

By product

By region

Cannabis Flower brings in 74% of revenue. Cannabis Extracts grew fastest, by 26% a year.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy